Daily Update: FDA PreCheck Launch, Sanofi Venglustat Results
The FDA’s new PreCheck pilot program opens for applications as the agency moves to reshore pharmaceutical manufacturing. Sanofi’s venglustat delivers a split verdict—winning in Gaucher Type 3 but missing in Fabry disease. HHS commits $100 million to abstinence-based recovery pilots, and Exelixis secures NDA acceptance for zanzalintinib in colorectal cancer.
📅 Week Ahead
Wed 2/4: Amgen Q4 earnings — watch biosimilar margin commentary
Thu 2/5: EU CHMP meeting outcomes expected
Fri 2/6: January Jobs Report — healthcare hiring as macro signal
Top Story: FDA PreCheck Pilot Opens for Applications
What Happened: The FDA began accepting applications on February 1, 2026 for the PreCheck Pilot Program, a new initiative designed to strengthen the domestic pharmaceutical supply chain by creating a more predictable regulatory pathway for new U.S.-based manufacturing facilities.
Commissioner Makary’s Framing: FDA Commissioner Marty Makary positioned the program as a reversal of decades-long offshoring trends, stating the PreCheck program represents “bold steps to bring [pharmaceutical manufacturing] back” after “35 years of globalists taking pharmaceutical manufacturing overseas.”
Program Structure: PreCheck operates in two phases. Phase 1, the Facility Readiness Phase, provides selected manufacturers with early technical guidance through pre-operational reviews and facility-specific Drug Master Files—allowing FDA evaluation of manufacturing elements before any drug application is submitted. Phase 2, the Application Submission Phase, builds on this foundation through pre-submission meetings and inspections to resolve issues and expedite assessments.
Selection Criteria: Facilities will be selected based on alignment with national priorities including products to be manufactured, phase of facility development, timeline to producing pharmaceutical products for the U.S. market, and innovation in facility development. Additional priority consideration will be given to facilities producing critical medications.
Timeline: PreCheck finalists will be notified by April 1, 2026, with final selections made by June 30, 2026.
Context: As of 2025, approximately 53% of branded drug products and 69% of generic drug products are manufactured outside the United States. Only 11% of API manufacturers are U.S.-based, compared to 22% in China and 44% in India. The program follows Executive Order 14293, “Regulatory Relief to Promote Domestic Production of Critical Medicines,” issued May 5, 2025.
🚩 Contrarian Flag: PreCheck Hype vs. Reality
The pilot selects finalists by April, final cohort by June—but actual PreCheck benefits won’t flow until 2027+. Near-term CDMO re-ratings may be pricing in optionality that takes 18+ months to materialize. Watch for “sell the news” if early applicant lists disappoint.
Clinical Data & Pipeline
Sanofi Venglustat: Gaucher Type 3 Win, Fabry Disease Miss
What Happened: Sanofi announced results from two Phase 3 trials of venglustat, an oral substrate reduction therapy, with divergent outcomes that will reshape the company’s rare disease strategy.
📊 Sanofi Venglustat Phase 3 Results
LEAP2MONO (Gaucher Type 3): Met all primary endpoints; demonstrated superiority over enzyme replacement therapy (ERT) in neurological symptoms
PERIDOT (Fabry Disease): Failed to meet primary patient-reported pain endpoint
Regulatory Path: Sanofi plans global regulatory filings for Gaucher Type 3
Next Steps: Second Fabry Phase 3 trial (CARAT) ongoing
LEAP2MONO Details: The trial evaluated venglustat in patients with Gaucher disease Type 3 (GD3), a rare lysosomal storage disorder characterized by neurological involvement in addition to systemic manifestations. Results showed superiority over current standard-of-care enzyme replacement therapy across neurological endpoints—a meaningful advance given ERT’s inability to cross the blood-brain barrier.
PERIDOT Miss: The Fabry disease trial failed its primary endpoint of patient-reported pain reduction. Sanofi has not abandoned Fabry, however, with the CARAT Phase 3 trial still ongoing and potentially offering a different patient population or dosing strategy.
Strategic Context: Venglustat is an oral, once-daily substrate reduction therapy that works by reducing the production of glycosphingolipids that accumulate in lysosomal storage disorders. A successful oral therapy in GD3 would represent a significant advance over current infusion-based treatments, particularly for neurological manifestations.
J&J Erleada: Real-World Evidence vs. Darolutamide
What Happened: Johnson & Johnson presented real-world evidence at the 36th Annual International Prostate Cancer Update showing Erleada (apalutamide) significantly outperformed darolutamide in metastatic castration-sensitive prostate cancer (mCSPC).
📊 Erleada Real-World Data
Primary Finding: 51% reduction in risk of death vs. darolutamide
Hazard Ratio: 0.49 (95% CI: 0.30-0.83; P=0.007)
Population: 1,460 Erleada patients vs. 287 darolutamide patients
Time Period: August 2022 – June 2025
Methodology: Propensity score matching (IPTW)
Clinical Implications: These data enter an increasingly competitive androgen receptor inhibitor landscape where real-world evidence is becoming a key differentiator for payer discussions and clinical guideline positioning. The magnitude of the overall survival difference (51% risk reduction) is striking, though the retrospective design and population imbalance warrant careful interpretation.
Competitive Context: Both Erleada and darolutamide (Nubeqa, from Bayer) are second-generation androgen receptor inhibitors approved in mCSPC. Darolutamide has positioned on its tolerability profile, particularly lower CNS penetration. These data give J&J a potential counter-narrative focused on efficacy outcomes.
Dogwood Therapeutics: Halneuron Enrollment Milestone
What Happened: Dogwood Therapeutics announced that its Phase 2b HALT-CINP trial of halneuron in chemotherapy-induced neuropathic pain (CINP) has surpassed 50% enrollment.
Trial Design: HALT-CINP is evaluating halneuron, a sodium channel blocker, in patients experiencing persistent neuropathic pain following chemotherapy—a condition affecting up to 40% of cancer survivors with no FDA-approved treatments.
Progress Signals: The company reported a low early termination rate of 4.3% among the 116 patients who have completed the trial, suggesting acceptable tolerability. Top-line results are expected in Q3 2026.
Unmet Need: CINP represents a significant quality-of-life burden for cancer survivors. Current management relies on repurposed drugs (gabapentinoids, duloxetine) with limited efficacy. A purpose-built therapy with positive Phase 2b data could attract significant partnership interest.
Regulatory & FDA Actions
Exelixis Zanzalintinib: NDA Accepted in mCRC
What Happened: The FDA accepted Exelixis’s New Drug Application (NDA) for zanzalintinib in combination with atezolizumab (Tecentriq) for the treatment of metastatic colorectal cancer (mCRC).
📋 Zanzalintinib NDA Details
Indication: Metastatic colorectal cancer (in combination with atezolizumab)
PDUFA Date: December 3, 2026
Supporting Data: Phase 3 STELLAR-303 trial
Key Finding: Overall survival improvement vs. regorafenib
About Zanzalintinib: The compound is Exelixis’s next-generation tyrosine kinase inhibitor targeting TAM receptors (TYRO3, AXL, MER), MET, and VEGFR—building on the company’s Cabometyx franchise with a refined target profile designed for combination with checkpoint inhibitors.
STELLAR-303 Trial: The Phase 3 study demonstrated an overall survival improvement versus regorafenib (Stivarga), the current standard in refractory mCRC. If approved, this positions Exelixis to challenge Stivarga’s remaining refractory CRC share—a roughly $400 million annual opportunity Bayer has been quietly ceding.
Strategic Significance: The filing represents Exelixis’s most advanced diversification effort beyond Cabometyx in renal and liver cancers. The December 2026 PDUFA date sets up a potential launch in early 2027.
Policy & Public Health
HHS STREETS Initiative: $100M for Recovery Pilots
What Happened: The Department of Health and Human Services announced the STREETS Initiative—Safety Through Recovery, Engagement and Evidence-based Treatment and Supports—a $100 million investment in what HHS calls the “Great American Recovery.”
🏛️ HHS STREETS Initiative
Investment: $100 million
Scope: Eight pilot cities (unspecified)
Focus Areas: Abstinence-based recovery, psychiatric care, medical stabilization
Policy Change: MOUD now eligible for 50% federal match as prevention services
Program Philosophy: The initiative emphasizes abstinence-based recovery models alongside medication for opioid use disorder (MOUD), psychiatric care, and medical stabilization. The framing represents a notable shift in federal rhetoric around addiction treatment, though the practical impact will depend on how pilot cities implement the flexible guidance.
MOUD Policy Shift: Significantly, the announcement includes making medications for opioid use disorder eligible for a 50% federal match as prevention services—potentially expanding access to buprenorphine and methadone programs through state Medicaid budgets.
What to Watch: The eight pilot cities have not yet been named. Site selection will signal whether the program targets high-overdose-burden urban centers, rural communities, or a geographic mix.
Lancet Meta-Analysis: Paracetamol Safety in Pregnancy
What Happened: A systematic review and meta-analysis published in The Lancet Obstetrics, Gynaecology & Women’s Health in mid-January found no evidence linking prenatal paracetamol (acetaminophen) use to autism, ADHD, or intellectual disability in children.
Study Details: The analysis reviewed 43 studies, with 17 included in the meta-analysis. Critically, sibling comparison studies—which control for shared genetic and environmental factors—showed no increased risk, strengthening the causal inference.
Clinical Significance: The findings provide reassurance for pregnant women and their physicians navigating pain management during pregnancy. Previous observational studies had raised concerns, leading to cautionary guidance that may have left pain undertreated in some pregnant patients.
Deals, Financing & Corporate
Santé Ventures Closes $330M Fund V
What Happened: Austin-based Santé Ventures closed its fifth fund at $330 million, exceeding its $300 million target and marking the firm’s largest fund to date.
Investment Focus: The fund will target early-stage biotech, medtech, and digitally enabled healthcare companies—continuing Santé’s strategy of backing companies at the Series A and B stages with hands-on operational support.
Market Signal: The oversubscription reflects continued LP appetite for healthcare venture despite 2024-2025’s broader funding pullback. Early-stage funds with differentiated networks and operational value-add are still raising successfully.
Optellum-NHS Partnership: AI-Driven Lung Cancer Pathway
What Happened: NHS England selected Optellum late last week to deploy AI-driven lung cancer diagnostic pathways, combining the company’s Virtual Nodule Clinic AI with robotic-assisted bronchoscopy.
Implementation: The partnership launches at Guy’s and St Thomas’ NHS Foundation Trust, with plans to expand to King’s College Hospital. The integrated pathway aims to accelerate diagnosis of indeterminate pulmonary nodules—a common incidental finding that creates significant diagnostic uncertainty and patient anxiety.
Strategic Context: The NHS selection validates Optellum’s clinical pathway approach versus point-solution AI. By integrating AI triage with procedural guidance, the company addresses the full diagnostic workflow rather than a single decision point.
Staar Surgical: Interim Co-CEO Structure Following Alcon Merger Collapse
What Happened: Following the collapse of its proposed Alcon merger and the departure of CEO Stephen Farrell on January 31, Staar Surgical appointed Warren Foust (President/COO) and Deborah Andrews (CFO) as interim co-CEOs effective February 1, 2026.
Context: The co-CEO structure is explicitly temporary while the company conducts a global search for a permanent chief executive. The structure suggests the board wants operational and financial continuity during what will likely be a multi-month search process.
What to Watch: Staar’s implantable lens technology remains differentiated, but strategic optionality has narrowed post-Alcon. The new CEO’s mandate will likely include evaluating alternative paths to scale—whether through another strategic combination, partnership expansion, or accelerated organic investment.
Psyence Biomedical: Second Reverse Split in Eight Months
What Happened: Psyence Biomedical executed a 1-for-6.25 reverse stock split effective February 2, 2026, reducing outstanding shares from approximately 6.4 million to 1.0 million to maintain Nasdaq listing requirements.
Context: This marks the company’s second reverse split in eight months, following a 1-for-7.97 split in May 2025. Sequential reverse splits typically signal continued difficulty generating investor interest and maintaining minimum bid price requirements—a pattern common among clinical-stage psychedelic companies facing extended timelines to regulatory clarity.
Market Context
EY Firepower Report: $2.1 Trillion Ready for Deals
What It Says: EY’s January 2026 Firepower Report calculates $2.1 trillion in available M&A capacity across the life sciences sector, with 81% year-over-year growth in M&A spending in 2025 ($240 billion versus $130 billion in 2024).
Quality Over Quantity: Deal volume actually declined 12% in 2025, but average deal size increased 107%—reflecting a shift toward larger, more strategic transactions rather than the “smaller, smarter” deals that characterized 2024.
Patent Cliff Pressure: The report notes that 65% of big pharma revenues now derive from dealmaking, with $300 billion in industry revenues threatened by patent expirations through 2028. This structural pressure makes continued M&A activity nearly inevitable.
Bristol Myers Squibb: Post-Cliff Portfolio Pivot
Strategic Positioning: At JPM26 (January 12-15, 2026), CEO Christopher Boerner framed 2026 as a “reacceleration year” built on scaling the company’s new product portfolio to offset the approaching Opdivo and Eliquis patent cliffs (both approximately 2028).
Pipeline Catalysts: BMS expects six pivotal readouts in 2026 and projects the potential to launch up to 10 new medicines by 2030—an aggressive timeline that depends on consistent clinical execution across oncology, cardiovascular, and neuroscience programs.
Investor Lens: The question for BMS investors is whether the new product portfolio can generate enough revenue by 2028-2029 to offset what could be $15+ billion in at-risk sales from Opdivo and Eliquis. The 2026 readouts will provide critical visibility into that trajectory.
🔒 Pro Intelligence: Staar Surgical Scenario Analysis
With the Alcon merger collapsed and interim co-CEOs in place, what happens next for Staar’s differentiated ICL technology?
🔒 Scenario probability matrix: Strategic re-engagement, standalone acceleration, or activist pressure?
🔒 Buyer universe analysis: Who else could acquire Staar and at what valuation?
🔒 Trade flow implications: Positioning for each scenario
Pro members get scenario analysis, probability matrices, and trade flow intelligence for situations like this—before the market prices them in.Upgrade to Pro →
Related BioMed Nexus Coverage
Manufacturing & Supply Chain
- Pharmaceutical Reshoring: Executive Orders, Incentives, and Reality
- CDMO Landscape: Who Benefits from Domestic Manufacturing Push
- API Dependency: Mapping Critical Medicine Supply Chains
Rare Disease & Gene Therapy
- Substrate Reduction vs. ERT: Competitive Dynamics in Lysosomal Storage
- Oral Therapies in Rare Disease: The Convenience Premium
- Gaucher Disease Market: Current Players and Pipeline Entrants
Oncology
- Colorectal Cancer: TKI + Checkpoint Inhibitor Combinations
- Real-World Evidence in Oncology: Payer and Regulatory Implications
- Prostate Cancer AR Inhibitor Wars: Erleada, Nubeqa, Xtandi Positioning
Frequently Asked Questions
What is the FDA PreCheck Pilot Program?
PreCheck is a new FDA initiative designed to strengthen domestic pharmaceutical manufacturing by providing early regulatory engagement and a more predictable pathway for new U.S.-based production facilities. Selected companies receive FDA technical guidance during facility construction—before submitting drug applications—potentially accelerating the approval process for both the facility and future products.
When will PreCheck selections be announced?
Finalists will be notified by April 1, 2026, with final selections announced by June 30, 2026. However, actual PreCheck benefits (streamlined facility assessments, expedited reviews) won’t flow until facilities complete the program phases, likely 2027 or later.
What do Sanofi’s venglustat results mean for patients?
For Gaucher Type 3 patients, the LEAP2MONO results represent potentially transformative news—an oral therapy that demonstrated superiority over infusion-based enzyme replacement therapy, particularly for neurological symptoms that ERT cannot address. For Fabry patients, the PERIDOT miss is disappointing, though Sanofi’s ongoing CARAT trial may still yield positive results in a different patient population or with different endpoints.
What is zanzalintinib and why does it matter?
Zanzalintinib is Exelixis’s next-generation tyrosine kinase inhibitor designed to work synergistically with checkpoint inhibitors like Tecentriq. If approved, it would give Exelixis a commercial presence in colorectal cancer—diversifying beyond its current Cabometyx-dominated portfolio in renal and liver cancers—and potentially displacing Bayer’s Stivarga in the refractory setting.
What is the HHS STREETS Initiative?
STREETS (Safety Through Recovery, Engagement and Evidence-based Treatment and Supports) is a $100 million HHS program launching in eight pilot cities. It emphasizes abstinence-based recovery alongside medication-assisted treatment, psychiatric care, and medical stabilization. Notably, it makes medications for opioid use disorder eligible for enhanced federal matching funds as prevention services.
Should pregnant women be concerned about paracetamol use?
Based on the recent Lancet meta-analysis, no. The comprehensive review of 43 studies found no evidence linking prenatal paracetamol (acetaminophen) use to autism, ADHD, or intellectual disability. Sibling comparison studies—which provide strong control for genetic and environmental factors—showed no increased risk. As always, pregnant women should consult their physicians about pain management options.
What’s happening with Staar Surgical?
Following the collapse of its Alcon merger and CEO departure, Staar has appointed interim co-CEOs (its President/COO and CFO) while conducting a global search for permanent leadership. The company’s implantable lens technology remains differentiated, but strategic optionality has narrowed. The new CEO’s mandate will likely include evaluating alternative paths to scale.
Stay Ahead of the Market
The investors and executives reading this article at 6 AM will act on these insights before the market opens. The question is whether you’ll be among them—or reacting to moves others made first.
BioMed Nexus Daily — Free
Join 12,000+ healthcare professionals
The essential morning briefing for biotech, medtech, and pharma. Delivered before market open, every trading day.
- Market-moving news and overnight developments
- Key catalysts and earnings on deck
- Regulatory decisions and clinical data releases
No spam. Unsubscribe anytime. Read by analysts at Goldman, Morgan Stanley, and JP Morgan.
BioMed Nexus Pro — $395/year
For serious investors and industry operators
Institutional-grade analysis that gives you an edge. The same frameworks used by hedge funds and BD teams.
Everything in Free, plus:
- Full Weekday Pro Intelligence (Monday–Friday)
- 30-Day Catalyst Watch & Risk Outlook Matrix
- Tomorrow’s Top 5 Near-Term Catalysts Across Biotech & Medtech
- Trial Decoder, plain-English reads on key clinical data
- Money Flow Monday, financings, BD moves, and quiet deal activity
- Deal Heat Tracker with professional, institutional-grade analysis
Annual billing with a single invoice, easy to expense as a research or professional subscription.
“BioMed Nexus is the first thing I read every morning. It’s replaced three other newsletters.”
— Director of Business Development, Top 10 Pharma
BioMed Nexus provides daily intelligence for leaders in biotech, medtech, and pharma. This daily brief is intended for context, not investment recommendation.
